Skip to content

Theriva Biologics, Inc.

TOVX

CIK 0000894158

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$17.03M
+6.8% YoY Q1 May 2026
EPS Diluted (TTM)
−$3.98
+89.1% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$17.73M
Q1 May 2026
Cash
$14.43M
Q1 May 2026
Total Debt
$1.73M
Q1 May 2026
Shares Outstanding
45.89M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings